This article was originally published in The Gray Sheet
Phase III clinical trials for the AngioMARK (MS-325) injectable MRI contrast imaging agent for peripheral vascular indications are slated to begin in early 1999, Epix President and CEO Mike Webb reports Nov. 30 at the BancBoston Robertson Stephens conference in New York City. Data from Phase II clinicals were presented the same week at the Radiological Society of North America meeting in Chicago. The company expects to file a new drug application with FDA in the first half of 2000, Webb says
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.